RCUS (Arcus Biosciences) LT-Debt-to-Total-Asset: 0.10 (As of Mar. 2026)

What is Arcus Biosciences LT-Debt-to-Total-Asset?

Arcus Biosciences RCUS +2.48% 46 LT-Debt-to-Total-Asset is 0.10 as of Mar. 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.76 (Significantly Overvalued). The stock has 6 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Arcus Biosciences's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.10.

Arcus Biosciences's long-term debt to total assets ratio increased from Mar. 2025 (0.04) to Mar. 2026 (0.10). It may suggest that Arcus Biosciences is progressively becoming more dependent on debt to grow their business.

Arcus Biosciences (NYSE:RCUS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Arcus Biosciences LT-Debt-to-Total-Asset Related Terms

Arcus Biosciences LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Arcus Biosciences's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcus Biosciences LT-Debt-to-Total-Asset Chart

Arcus Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.04

0.09

Arcus Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.09	0.10	0.09	0.10

46GF Score

Arcus Biosciences Inc RCUS

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Arcus Biosciences LT-Debt-to-Total-Asset Calculation

Arcus Biosciences's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	99	/	1139
	=	0.09

Arcus Biosciences's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	100	/	997
	=	0.10

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.10 mean?

Arcus Biosciences (RCUS) has a LT-Debt-to-Total-Asset of 0.10 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Arcus Biosciences and its competitors.

Is Arcus Biosciences' LT-Debt-to-Total-Asset too high?

Arcus Biosciences' current LT-Debt-to-Total-Asset is 0.10. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Arcus Biosciences' LT-Debt-to-Total-Asset compare to NAMS and CRNX?

Arcus Biosciences' LT-Debt-to-Total-Asset of 0.10 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Biotechnology company?

A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Arcus Biosciences and its competitors. Arcus Biosciences's current LT-Debt-to-Total-Asset is 0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Arcus Biosciences stock overvalued right now?

Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.76, compared to a current price of $31.00 — trading 125.3% above its estimated fair value. The current LT-Debt-to-Total-Asset is 0.10. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current LT-Debt-to-Total-Asset is 0.10 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $31.00 is trading 125.3% above its estimated GF Value™ of $13.76. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

LT-Debt-to-Total-Asset: 0.10
GF Value™: $13.76 vs. price of $31.00 (125.3% above fair value)
GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies NAMS CRNX CPRX RLAY DNLI BEAM ELVN IDYA PBLS ACAD VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 3928 Point Eden Way, Hayward, CA, USA, 94545

Website https://www.arcusbio.com

Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.

46GF Score

Get the complete analysis for RCUS

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.00

Price

$13.76

GF Value

View RCUS Analysis

See LT-Debt-to-Total-Asset data for all stocks →